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Abstract: The principal Epstein-Barr virus (EBV) oncoprotein, Latent Membrane Protein 
1 (LMP1), is expressed in most EBV-associated human malignancies. LMP1 mimics CD40 
receptor signaling to provide infected cells with constitutive NF-κB, MAP kinase, IRF7, 
and PI3 kinase pathway stimulation. EBV-transformed B-cells are particularly dependent 
on constitutive NF-κB activity, and rapidly undergo apoptosis upon NF-κB blockade. Here, 
we review LMP1 function, with special attention to current understanding of the molecular 
mechanisms of LMP1-mediated NF-κB and IRF7 pathway activation. Recent advances 
include the elucidation of transmembrane motifs important for LMP1 trafficking and 
ligand-independent signaling, analysis of genome-wide LMP1 gene targets, and the 
identification of novel cell proteins that mediate LMP1 NF-κB and IRF7 pathway activation.  
Keywords: herpesvirus; apoptosis; cancer; innate immunity; transformation; integral 
membrane protein; signal transduction; proliferation; ubiquitin; lymphoma; oncogene 
 
1. Introduction  
Epstein-Barr virus (EBV) is a gamma-herpesvirus that infects >90% of people worldwide, is the 
etiologic agent of infectious mononucleosis, and is associated with multiple human malignancies. 
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Upon primary infection, EBV initially infects and may replicate in oropharyngeal epithelial cells [1,2]. 
EBV gains access to the B-cell compartment, where it drives robust B-cell proliferation through 
expression of six EBV nuclear antigens, multiple non-coding RNAs, and two integral membrane 
proteins, LMP1 and LMP2A [3,4]. Infected cells then enter lymph node germinal centers, where EBV 
gene expression is down-modulated, presumably to limit immune-detection. EBV subsequently 
establishes persistent infection of the memory B-cell compartment, from which it periodically 
reactivates [4–6].  
The principal viral oncoprotein, LMP1, transforms rodent fibroblasts [7]. Transgenic LMP1 
expression in murine models promotes the development of B-cell lymphomas and carcinomas [8–11]. 
Similarly, LMP1 expression is detectable in multiple human malignancies, where it may play a causal 
role. In particular, with T-cell immune-suppression, LMP1 is frequently expressed in proliferating  
B-cells of patients with lymphoproliferative disorders. These include post-transplant lymphoproliferative 
disorders and lymphomas in HIV-infected people [12]. EBV and LMP1 are also increasingly   
detected in diffuse-large B-cell lymphomas of the elderly [13]. In both immune-compromised and 
immunocompetent hosts, EBV and LMP1 are frequently present in the malignant Reed-Sternberg cell 
of Hodgkin Lymphoma (HL) [4,14–16]. Indeed, despite the success of antiretroviral therapy for human 
immunodeficiency virus, the risk of HIV-associated EBV-positive Hodgkin lymphoma has not 
decreased [17]. In immunocompetent hosts, LMP1 is expressed in a subset of anaplastic nasopharyngeal 
carcinomas (NPC) [18–20]. NPC is one of the most prevalent EBV-associated malignancies, and has a 
striking 50-fold higher incidence rate in southern China than in the Western world [21]. LMP1 is 
frequently expressed in these malignancies [15]. While latent EBV infection is detectable in   
roughly 10% of gastric carcinomas worldwide, only a subset appear to express LMP1 [22].  
As described in further detail below, LMP1 signals through two cytoplasmic domains. Both 
domains are necessary for efficient B-cell conversion to immortal lymphoblasts (LCLs) [23–26]. 
LMP1 induces cell survival and growth through ligand-independent activation of multiple cell 
pathways. These include nuclear factor-κB (NF-κB), mitogen-activated protein kinase (MAPK), 
interferon-regulatory factor 7 (IRF7), and phosphatidylinositol 3-kinase (PI3K) pathways [27–29].  
NF-κB transcription factors (TFs) are comprised of the REL-homology domain proteins p50, p52, 
RelA (also called p65), RelB, and cREL [30]. NF-κB TFs control lymphoid cell proliferation, 
differentiation and survival, and are critically important regulators of normal and pathological innate 
and adaptive immune responses. Inhibitory IκB proteins sequester NF-κB TFs in the cytosol to tightly 
restrict basal activity. Upon activation, receptor cytoplasmic domains initiate signal transduction 
cascades, referred to as NF-κB pathways [31]. Two major NF-κB pathways are recognized, and are 
termed the canonical and non-canonical NF-κB pathways. The cytosolic phase of NF-κB pathways 
culminates in IκB degradation, which allows NF-κB TF nuclear translocation. Post-translational 
modifications further activate NF-κB TFs, optimizing their binding to DNA κB sites and 
transcriptional regulation. Negative feedback loops tightly control NF-κB activation and terminate 
signaling upon stimulus withdrawal. While physiologic NF-κB activation is essential for lymphocyte 
development and activation, hyperactive NF-κB signaling promotes inflammatory diseases and 
malignant transformation [30].  
Interferon regulatory factor (IRF) 7 is a key regulator of Type 1 IFN production [32] and belongs to 
a family of 9 human IRF genes [33]. Interestingly, the IRF family underwent co-evolution with   V
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Other than a 5-residue tumor necrosis factor (TNF) receptor-associated factor (TRAF) binding 
motif, LMP1 does not exhibit amino acid similarity with CD40 (see below). Nonetheless, LMP1 and 
CD40 activate remarkably similar signal transduction cascades. TES1 and TES2 independently 
activate signal transduction pathways, and efficient long-term LCL outgrowth requires signaling from 
both domains [28].  
3. LMP1 Transmembrane Domains Enable Constitutive LMP1 C-terminal Tail Signaling 
The six LMP1 transmembrane domains (TM1-6) confer ligand-independent oligomerization, 
trafficking to membrane lipid rafts, and constitutive LMP1 C-terminal tail signaling [28]. Indeed, the 
cytoplasmic tails of CD40, FAS, TNFR1, and TNFR2 constitutively signal when fused to the LMP1  
N-terminus and TM domains [43–45]. By contrast, when fused to the CD40 extracellular receptor and 
transmembrane domain, the LMP1 C-terminal tail signals only in response to CD40 ligand   
stimulation [46]. Transgenic mice that express this CD40/LMP1 fusion protein, but not endogenous 
CD40, still have normal B-cell development, activation, class-switch recombination, and germinal 
center formation [46]. However, LMP1 signaling, in this context, drives class-switch recombination to 
IgG1 independent of cytokines. How then do the LMP1 TM domains enable cytoplasmic tail signaling? 
LMP1 TM residues important for LMP1 aggregation and trafficking have been identified through 
mutagenesis approaches (Figure 1). Deletion of LMP1 TM1-2 abrogates LMP1-mediated NF-κB 
activation, whereas deletion of LMP1 TM3-6 reduces LMP1-mediated NF-κB activation by ~60% [47]. 
Alanine mutagenesis of highly conserved human and rhesus EBV LMP1 TM1 residues identified a 
FWLY38-41 motif that is important for both LMP1 multimerization and lipid raft trafficking. Indeed, 
mutation of FWLY38-41 to AALA38-41 impairs LMP1 targeting to cholesterol and sphingolipid-rich lipid 
raft membrane microdomains, blocks TRAF3 recruitment, and markedly reduces LMP1-mediated   
NF-κB activation. Interestingly, FWLY38-41 also promotes intramolecular association between the 
LMP1 TM1-2 and TM3-6 domains. Additional intra-membrane associations further contribute to 
LMP1 aggregation and activation of LMP1 signaling [28,47].  
LMP1 contains putative leucine heptad motifs in TM1 and TM6. Leucine heptads, which form 
leucine zipper-like structures, mediate protein-protein interactions [48]. Indeed, an important role for 
the TM1 leucine heptad is supported by mutagenesis studies. Alanine mutation of the TM1 leucine 
heptadimpairs LMP1-mediated NF-κB activation and B-cell transformation [49,50]. By contrast, 
mutation of the TM6 leucine heptad has minimal effects on LMP1 signaling [49]. The TM1 leucine 
heptad promotes LMP1 lipid rafts trafficking [50], where LMP1 recruits key signaling components. 
Likewise, LMP1 TM3-4 associate with the Golgi and late endosome protein prenylated rab acceptor 1 
(PRA1). This association is important for LMP1 endoplasmic reticulum exit and initiation of   
C-terminal signal transduction [51]. 
Interestingly, LMP1 TM domains contain several charged and polar residues, which may play 
important roles in LMP1 aggregation. Some, but not all, LMP1 alleles contain an aspartic acid at 
residue 150. In the context of the B95.8 strain LMP1 TM5 domain, aspartic acid 150 (D150) may 
promote LMP1 multimerization. Alanine mutagenesis of D150 abrogates the ability of TM5 to 
homotrimerize in detergent micelles and reduces LMP1-mediated NF-κB activation in transfected 
cells, without substantially altering LMP1’s subcellular distribution [52]. Interestingly, the effect of Viruses 2013, 5  1591 
 
 
D150 may be context dependent. In a recent analysis of LMP1 alleles from clinical EBV isolates, 
many LMP1s do not contain an aspartic acid at in TM5 [53]. EBV isolates with non-polar amino acids 
at position 150 nonetheless signal as well, or in some cases better, than B95.8 LMP1 in reporter assays. 
Interestingly, this increased NF-κB activity was nonetheless mapped to the clinical isolate LMP1 TM 
domains. Additional LMP1 TM amino acid substitutions (relative to B95.8 LMP1) may compensate 
for the absence of D150.  
4. LMP1-Mediated Canonical NF-κB Activation 
TES2 predominantly activates the canonical NF-κB pathway (Figure 2). As described in more detail 
below, a hallmark of canonical NF-κB pathways is the activation of the IκB kinase (IKK) complex, 
comprised of the essential regulatory IKKγ (or NEMO) scaffold protein and the kinases IKKα and 
IKKβ. IKK phosphorylates the NF-κB inhibitor IκBα, which stimulates its rapid proteasomal 
degradation [30]. IκBα turnover allows canonical pathway NF-κB transcription factors, in particular 
the RelA/p50 heterodimer, to translocate to the nucleus. 
Since LMP1 lacks intrinsic enzymatic activity, it recruits and activates enzymes. The K63-ubiquitin 
E3 ligase TRAF6 appears to be the first enzyme activated by TES2 [54–57]. While TRAF6 has been 
reported to bind to TES1 in murine B cells [58], we have been unable to detect a direct association 
between TES2 and TRAF6. How then does TES2 activate TRAF6? Multiple proteins have been 
suggested to bind directly to TES2, including RIP1 and TRADD [59]. TRADD knockout in DG75  
B-cells abrogates TES2-mediated IKKβ recruitment and activation [60]. However, TRADD may not 
participate directly in TRAF6 activation, as TRADD deficiency does not impair LMP1-induced JNK 
activation, which is dependent on TRAF6 activation [60]. Furthermore, LMP1 may use TRADD in a 
cell-type specific fashion, as TRADD knockdown in 293 cells caused significant impairment of   
TNFα-mediated, but not TES2-mediated NF-κB activation [55,61]. Likewise, RIP1 may not be 
required for TES2-mediated NF-κB activation, as RIP1 knockdown in 293 cells and absence of 
detectable RIP1 protein in chemically mutagenized Jurkat T-cells do not impair TES2-mediated   
NF-κB activation [61,62]. 
Multiple adaptor proteins have been suggested to link LMP1 TES2 to TRAF6, including BS69 [63]. 
We found that the brain-expressed (BEX) family proteins BEX3 (also called nerve growth factor 
receptor associated protein 1, or NGFRAP1) and BEX5 associate with LMP1, and that BEX3/5 
knockdown markedly impairs TES2-mediated IKK activation [61]. Interestingly, the p75 nerve growth 
factor (NGF) receptor, a member of the TNFα-receptor superfamily, binds multiple BEX family 
members [64], and BEX2 potentiates NGF-mediated NF-κB activation in breast cancer cells [65]. 
Recently, the TRAF2- and NCK-interacting kinase TNIK was identified as a novel TES2 interactor [66]. 
TNIK knockdown impairs LMP1-mediated IKK activation in 293 cells by nearly 50%, and diminishes 
LCL growth and survival. Interestingly, the N-terminal TNIK kinase domain is important for   
LMP1-mediated canonical NF-κB activation, whereas its C-terminal scaffold domain instead promotes 
JNK pathway activation [66].  
LMP1 TES2 activates TRAF6 K63-ubiquitin ligase activity and promotes TRAF6   
auto-K63-ubiquitination [54–56,58,67]. Indeed, TRAF6 knockdown strongly abrogates TES2-mediated 
NF-κB activation, and TRAF6 siRNAs were amongst the strongest TES2/NF-κB inhibitors in our Viruses 2013, 5  1592 
 
 
genome-wide siRNA screen. Likewise, disruption of UBC13, TRAF6’s E2 ubiquitin ligase, impairs 
TES2-mediated NF-κB activation [56,61]. K63-ubiquitin chains recruit the homologous zinc-finger 
proteins TAB2 and TAB3, which in turn activate the kinase TAK1 (Figure 2). Further supporting an 
important role for K63-ubiquitin downstream of LMP1, combined TAB2/3 depletion impairs   
LMP1-mediated IKK activation [56]. Activated TAK1 phosphorylates downstream targets, in 
particular the IKK kinase activation loops. While TAK1 activity is obligatory for most canonical   
NF-κB pathways, TAK1 knockdown reduced TES2 NF-κB activation by only 40%–50% [61], and 
similar results have been observed in TAK1 deficient MEFs [68]. Thus, LMP1 may use additional 
kinase(s) in a partially-redundant manner with TAK1 [61]. Interestingly, our siRNA analysis indicates 
that several additional kinases are important for LMP1-mediated IKK activation (Figure 2). Further 
studies are required to determine whether any function at the level of TAK1.  
The recently discovered linear ubiquitin chain assembly complex (LUBAC) has increasingly been 
implicated in canonical pathway IKK activation, including by TNFα, interleukin 1-β (IL-1β), NOD2, 
and CD40 [69,70]. LUBAC is comprised of three components: the catalytic HOIP and HOIL-1L 
subunits, and the SHARPIN regulatory subunit. Interestingly, combined HOIP/HOIL-1L depletion 
impairs LMP1 TES2-mediated NF-κB activation by nearly 50% upstream of IKK complex 
activation [61]. By contrast, LUBAC depletion does not inhibit LMP1-mediated non-canonical NF-κB 
activation [71]. Open questions include how LMP1 signaling recruits and activates LUBAC to 
participate in downstream signaling, and the identification of cell LUBAC targets. While CD40 
recruits HOIL-1L [72], we have not yet been able to detect direct association between LMP1 and 
LUBAC subunits. Multiple receptors induce LUBAC to attach linear ubiquitin chains to RIP1,   
NEMO and likely additional cell proteins, thereby promoting the assembly and stabilization of 
receptor-associated signaling complexes [73,74]. Identification of LUBAC substrates downstream of 
LMP1 remains to be elucidated.  
HOIL-1L deficiency causes a fatal inherited disorder with chronic autoinflammation, recurrent 
invasive bacterial infection, and muscular amylopectinosis [75]. IL-1β responses are impaired in 
fibroblasts but are hyper-responsive in mononuclear leukocytes from patients with HOIL-1L 
deficiency. Interestingly, EBV-transformed lymphoblastoid cells can be established from patient-derived 
B-cells, despite the presence of HOIL-1L loss-of-expression or loss-of-function mutations [75]. 
Curiously, CD40-mediated IKK phosphorylation, IκBα degradation, and NF-κB activation are 
markedly impaired in HOIL-1L-deficient LCLs. Since LMP1 mimics CD40 signaling, and since 
LMP1 is necessary for EBV-mediated B-cell transformation, how then can HOIL-1L deficient LCLs 
be derived? Perhaps HOIP plays a more important role downstream LMP1 than CD40, and residual 
LUBAC activity in HOIL-1L deficient LCLs is sufficient for LMP1 canonical pathway activation. 
Indeed, Sharpin and RNF31 knockdown more strongly impair LMP1 TES2/NF-κB than HOIL-1L 
knockdown [61]. Alternatively, perhaps LMP1-mediated non-canonical activity is sufficient to support 
EBV-mediated B-cell transformation.  
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signaling to IKK, such as by regulating the stability of established TES2/NF-κB activation or 
inhibition pathway components. 
Most canonical NF-κB pathways require IKKβ, but not IKKα activity. Key IKK targets include 
IκBα and RelA. IKK-mediated IκBα serine 32,36 phosphorylation stimulates its ubiquitination and 
proteasomal degradation, which then allows nuclear translocation of the RelA/p50 heterodimer   
(Figure 2). Interestingly, TES2 uses IKKα and IKKβ in partially redundant manners. While depletion 
of either kinase partially impairs TES2-mediated IκBα phosphorylation, degradation, RelA serine 536 
phosphorylation, and reporter gene activation, combined IKKα/β depletion markedly blocks each of 
these, to a similar extent as NEMO depletion [61].  
Following NF-κB transcription factor nuclear translocation, additional cellular mechanisms are 
likely to further regulate LMP1-mediated NF-κB activation. Indeed, knockdown of multiple putative 
nuclear proteins impair LMP1 mediated NF-κB reporter gene activation without affecting IKK 
activation [61]. For instance, multiple independent siRNAs against the little characterized zinc finger 
protein ZC3H13 impair NF-κB activation by TES2, as well as TNFα and IL-1β [76]. By contrast, 
multiple ZC3H-family members negatively regulate canonical NF-κB pathways, including ZC3H12a, 
whose knockout causes a lethal autoimmune syndrome in mice [76]. Further studies are required to 
determine how ZC3H13 instead promotes nuclear NF-κB activation. Interestingly, the closely related 
zinc finger protein ZC3H18 is important for TES2-mediated IKK activation [61]. 
TES2 up-regulates multiple well-characterized negative NF-κB regulators, including IκBα, A20, 
CYLD, and ABIN1 [77]. Indeed, these are amongst the earliest and most-robustly TES2-induced genes 
in HEK-293 cells [77]. Proteasomal degradation and exosome secretion also limit LMP1 cell 
abundance and therefore signal strength [78]. Indeed, LMP1 associates with the late endosome marker 
CD63, and a substantial fraction of LMP1 exits cells by exosome secretion from nasopharyngeal 
carcinoma and LCLs [79]. CD63 association is critical for LMP1 exosome secretion. Despite its 
important role in LMP1 signaling, lipid raft association appears not to be critical for LMP1 sorting into 
exosomes [80]. LMP1-containing exosomes, obtained from NPC or LCL cultures, induce LMP1 signal 
transduction pathway activation in neighboring cells [81]. 
Of note, LMP1 TES1 also activates canonical NF-κB through an incompletely characterized 
pathway. An LMP1 mutant truncated after the TES1 domain (LMP1 1-231) initiates primary B-cell 
growth transformation in tissue culture, and the resulting LCLs have similar nuclear NF-κB complexes 
as wild-type LCLs, including p50/RelA and p50/cREL heterodimers [25]. Likewise, we have observed 
that LMP1 1-231 activates canonical NF-κB activation in HEK-293 cells. TES1-mediated canonical 
NF-κB activity is blocked by NEMO knockdown or by over-expression of an IκBα super-repressor [71].  
5. LMP1 Canonical NF-κB Gene Targets  
LMP1 up-regulates and down-regulates a significant number of cell genes in both epithelial and  
B-cells [16,77,82–84]. Differences in chromatin accessibility between B-cells and epithelial cells may 
strongly configure the transcriptional landscape in response to LMP1 [85]. Unfortunately, direct 
comparisons of LMP1 B-cell versus epithelial cell transcriptional effects are limited by differences in 
experimental design and microarray platforms used in published studies. Nonetheless, in both cell 
types, important gene targets include NF-κB pathway components and feedback regulators, proteins Viruses 2013, 5  1595 
 
 
important for cell cycle progression, blockade of apoptosis, immune-modulation, cytokines and 
cytokine receptors, and cell migration. In EBV-transformed lymphoblastoid cells, RelA binding is 
detectable at 58% of genes up-regulated by TES2 in HEK-293 cells [77].  
While TES2 activates the p38, JNK, ERK and NF-κB pathways, canonical NF-κB activity is critical 
for TES2 target genes effects in HEK-293 cells. Indeed, whereas TES2 causes >2-fold changes in 1916 
cell mRNAs, co-expression of an IκBα super-repressor together with TES2 decreases TES2 effects to 
only cell 5 mRNAs [77]. Of note, NF-κB inhibition has a strong, but less pronounced effect on LMP1 
target gene regulation in BL41 Burkitt lymphoma cells [84]. 
Interestingly, an important role for LMP1-mediated canonical NF-κΒ activation in cell metabolism 
and glucose uptake has recently been elucidated [86]. Likewise, LMP1 up-regulates the expression of 
the cell microRNA miR-34a in a canonical NF-κB-dependent manner [87].  
6. LMP1-Mediated Non-Canonical NF-κB Activation 
In unstimulated cells, the ubiquitin ligases TRAF2, TRAF3, cIAP1 and cIAP2 target the kinase 
MAP3K14 (also called NF-κB inducible kinase, or NIK) for degradation and thereby suppress the  
non-canonical NF-κB pathway [88]. Thus, although NIK is constitutively made, its levels do not 
accumulate in cells in the absence of stimulation. TRAF3 serves as an adaptor that recruits the 
TRAF2/cIAP1/2 ubiquitin ligase complex, which then attaches degradative K48-linked ubiquitin 
chains to NIK. Human cell receptors, such as CD40 and the BAFF receptor, activate non-canonical 
NF-κB activity by disrupting the TRAF2/3/cIAP1/2 complex. Receptor activation causes TRAF2 to 
attach K63-ubiquitin chains to cIAP1 and cIAP2, which are then redirected to K48-ubiquitinate 
TRAF3 and stimulate its rapid degradation. In the absence of TRAF3, NIK is stabilized, and upon 
reaching a threshold concentration, presumably auto-activates its kinase activity [89]. NIK in turn 
phosphorylates IKKα, which then phosphorylates the p100 NF-κB transcription factor precursor 
(Figure 2). P100 phosphorylation stimulates proteasomal cleavage of its C-terminal IκB domain, 
generating the active p52 form. P52 then translocates to the nucleus as a homodimer, or as a 
heterodimer with other NF-κB transcription factors, in particular RelB [88]. 
LMP1 TES1 strongly activates the non-canonical NF-κB pathway, by an incompletely understood 
mechanism. To initiate signaling, the TES1 PQQAT208 motif recruits TRAFs 1, 2, 3, and 5 [90,91]. 
Mutation of this site to AQAAA208 abolishes TES1-mediated non-canonical activation. However, in 
contrast to signaling by CD40 and BAFF receptors, TES1 has not been observed to trigger TRAF3 
degradation [92]. How then does TES1 activate the non-canonical pathway? Perhaps LMP1 sequesters 
sufficient TRAF3 away from TRAF2/cIAP1/2 complex to allow NIK to escape degradation. Indeed, 
the Herpesvirus ateles oncoprotein Tio activates non-canonical NF-kB by redistributing TRAF3 away 
from the cytosol in a ubiquitin-independent manner [93]. Alternatively, LMP1 may use TRAF3 to 
more directly activate non-canonical signaling by a unique mechanism [94]. Unfortunately, genetic 
analysis of TRAF2, TRAF3, and cIAP function downstream of LMP1 TES1 is complicated by   
high-level non-canonical NF-κB activity that results upon TRAF2 or TRAF3 depletion, even in the 
absence of stimulus. Though the precise mechanisms by which TES1 mediates NIK activation remain 
to be fully detailed, NIK has been established as a critical pathway component. Overexpression of a 
dominant-negative NIK mutant blocks TES1-mediated non-canonical activation in HEK-293 cells, and Viruses 2013, 5  1596 
 
 
TES1 non-canonical NF-κB activation is blocked in MEFs that lack functional NIK [95–97]. The zinc 
finger protein ZFP91 promotes K63-ubiquitination of NIK and up-regulates NIK activity, perhaps by 
promoting NIK stability or potentiating its kinase activity [98]. ZFP91 knockdown also impairs   
CD40-mediated non-canonical NF-κB activation. Whether ZFP91 similarly functions downstream of 
LMP1 TES1 awaits further analysis. Likely through phosphorylation by NIK, LMP1 triggers IKKα 
activation, p100 phosphorylation, and p100 processing to p52 (Figure 2). P52 heterodimers, in 
particular p52/RelB, translocate to the nucleus to modulate target gene expression. Of note, p52/RelA 
complexes are also abundantly generated [96]. 
As with the LMP1 canonical NF-κB pathway, little is known about the nuclear phase of the LMP1 
non-canonical NF-κB pathway, though additional regulatory mechanisms exist. Likewise, little is 
presently known about which genes are targeted by the LMP1-mediated canonical versus the   
non-canonical NF-κB pathways, the degree to which the two gene sets overlap, and the magnitude of 
canonical vs. non-canonical pathway effects on target gene regulation.  
7. LMP1/Atypical NF-κB Pathway Activation 
LMP1 TES1 signaling induces epidermal growth factor receptor (EGFR) expression, even in murine 
embryonic fibroblasts that lack IKKα, IKKβ, or IKKγ. This activity does however require TRAFs 2, 3, 
and NIK, and culminates in the activation of a complex of p50 homodimer and Bcl-3 [99].  
8. The LMP1/IRF7 Pathway 
Studies of the EBV EBNA1 Q promoter originally led to the identification and cloning of IRF7, 
where IRF7 was found to bind to an interferon-stimulated response element (ISRE) and to promote 
type III latency [100]. LMP1 not only up-regulates IRF7 expression, but also activates IRF7, likely 
through a direct association with LMP1 [101–103]. Indeed, the LMP1 TES2 domain and IRF7 strongly 
interact by yeast 2-hybrid analysis, suggesting that LMP1 and IRF7 may directly interact [101,103,104]  
(though it remains possible that an adaptor protein present in yeast could facilitate the observed 
association between LMP1 and IRF7). Indeed, immunofluorescence analysis demonstrates substantial 
co-localization between LMP1 and IRF7 in human B-cell lines [102]. The LMP1/IRF7 association r 
LMP1 residues 379–386 [101,103,104]. Interestingly, while TRADD and RIP1 bind to a similar region 
of LMP1, they appear not to be required for LMP1-mediated IRF7 recruitment. Indeed, mutation of 
LMP1 residues YYD386 to ID abrogates TRADD and RIP1, but not IRF7 recruitment. The LMP1 ID 
mutant nonetheless does not activate the IRF7 pathway, consistent with important roles for TRADD 
and/or RIP1 in LMP1-mediated IRF7 activation [101,103,104]. While TRAF6 is important for   
LMP1-mediated IRF7 activation, TRAF2 and TRAF3 are dispensable [101,103,104]. Interestingly, 
LMP1 promotes TRAF6 K63-linked ubiquitination of three C-terminal IRF7 residues (positions 444, 
446 and 452). Lysine to arginine mutation of these IRF7 residues abrogates IRF7 transactivation 
activity in response to either LMP1 or overexpression of an IRF7 kinase, IKKε. TRAF6-mediated 
IRF7 ubiquitination appears to be a prerequisite for its phosphorylation [104] (Figure 3).  
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IRF7 is predominantly expressed in lymphoid cells of the spleen, thymus and peripheral   
blood [108]. However, four NF-κB binding sites are present in the IRF7 gene promoter region,   
and LMP1 induces IRF7 expression in an NF-κB dependent manner [109,110]. Since IRF7   
likewise up-regulates LMP1 expression, LMP1 and IRF7 participate in a positive-feedback circuit  
(Figure 3) [109–111].  
Though elegant biochemical studies have established that LMP1 activates IRF7, the role of the 
LMP1/IRF7 pathway during EBV host infection remains to be fully characterized. Together with   
NF-κB, IRF7 may be responsible for the regulation of genes that contribute to cell growth and 
proliferation in EBV-transformed B-cells. Since both LMP1 and IRF7 have oncogenic properties, 
IRF7 may play an important role in EBV-associated malignancies. Indeed, IRF7 expression was 
frequently detected in LMP1-positive primary lymphomas of the human central nervous system, and 
the association between LMP1 and IRF7 expression was statistically significant. LMP1 and IRF7  
co-expression demonstrate additive effects on the NIH 3T3 cell growth transformation [112]. 
Identification of the full suite of LMP1/IRF7 target genes would significantly enhance current 
understanding of IRF7’s role downstream of LMP1. Thus, RNA profiling and phenotypic analysis of 
IRF7-depleted EBV-transformed cells, as well as IRF7 ChIP-Seq analysis, may further elucidate 
IRF7’s role in EBV-associated malignancies. Likewise, despite robust IRF7 activation, LCLs do not 
produce substantial amounts of type I interferon [35]. Why IRF7 activation in this context does not 
lead to more substantial type I IFN induction during EBV latency awaits further studies. 
Several negative regulators of the LMP1/IRF7 pathway have been identified. Perhaps attracted by 
robust IRF7 K63-ubiquitination, the deubiquitinating enzyme A20 is recruited to IRF7 and   
down-modulates its activity. A20 over-expression impairs LMP1-mediated IRF7 activation, whereas 
A20 knockdown enhances it [113]. This inhibitory effect requires the A20 deubiquitinase domain, but 
not its E3 ubiquitin ligase domain. Similarly, SUMOylation down-modulates IRF7 activity. LMP1 
associates with the SUMO conjugating enzyme UBC9 and promotes IRF7 SUMOylation, which 
promotes IRF7 stability, but negatively regulates IRF7 chromatin-binding [41,42] (Figure 3).  
9. Concluding Remarks 
Though much has been learned about how LMP1 activates NF-κB and IRF7 pathways, important 
questions remain. For instance, why are LMP1 TES1 and TES2 both important for EBV-mediated  
B-cell transformation? What cell target genes uniquely or commonly respond to LMP1-mediated IRF7, 
canonical or non-canonical NF-κB activation? Which NF-κB TFs are most important for the growth 
and survival of LMP1-positive epithelial versus B-cell malignancies? Rapidly advancing next-generation 
nucleic acid sequencing and ChIP-Seq technologies will enable increasingly precise characterization of 
these questions, both in model systems and importantly, in human EBV-associated malignancies. 
Systematic genetic analysis of LMP1-mediated non-canonical and IRF7-pathway activation may 
reveal novel pathway components specific to LMP1. Increasingly precise understanding of LMP1   
NF-κB and IRF7 pathways, as well as their target genes, promises to allow identification of targets 
whose inhibition selectively impairs the growth and survival of EBV-transformed cells, and ultimately 
to guide the development of rational therapeutic agents for LMP1-associated human malignancies.  
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